Life Sciences Research for Lifelong Health
Sharpe Lab 2019

Gareth Fearnley

Originally from God’s own county (Yorkshire), Gareth completed a degree in Biochemistry, followed by a PhD in Molecular and Cellular Biology at the University of Leeds with Dr Vas Ponnambalam. Here he studied how the vascular endothelial growth factor (VEGF)-A/VEGF receptor tyrosine kinase (RTK)-2 signalling axis modulated endothelial cell function, with a particular focus on differential regulation by individual VEGF-A splice isoforms.

After his PhD and many years focusing on the kinase side of signal transduction, Gareth decided to switch stance and study the antagonistic and relatively poorly understood role of phosphatases. In 2016, Gareth joined the laboratory of Dr Hayley Sharpe with the aim of better understanding the functional and mechanistic role of the receptor type protein tyrosine phosphatase (PTP), PTPRK. Currently, his research interests lie in identifying high confidence PTP substrates and how the redox regulation of PTPs impacts cellular function. In his spare time he enjoys music, real ale and online competitive gaming.

Latest Publications

Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.

Ighilahriz M, Benfodda M, Sharpe H

Journal of the European Academy of Dermatology and Venereology : JEADV
1468-3083: (2019)

PMID: 31187903

Grking the Smoothened signal.

Sharpe HJ, de Sauvage FJ

Science signaling
11 1937-9145: (2018)

PMID: 29438011

A new trick for an old lipid.

Sharpe H

5 2050-084X: (2016)

PMID: 27885984

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

Bonilla X, Parmentier L, King B

Nature genetics
48 1546-1718:398-406 (2016)

PMID: 26950094

Regulation of the oncoprotein Smoothened by small molecules.

Sharpe HJ, Wang W, Hannoush RN

Nature chemical biology
11 1552-4469:246-55 (2015)

PMID: 25785427

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

Sharpe HJ, Pau G, Dijkgraaf GJ

Cancer cell
27 1878-3686:327-41 (2015)

PMID: 25759019

Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.

Basset-Seguin N, Sharpe HJ, de Sauvage FJ

Molecular cancer therapeutics
14 1538-8514:633-41 (2015)

PMID: 25585509

Signaling: An oxysterol ligand for Smoothened.

Sharpe HJ, de Sauvage FJ

Nature chemical biology
8 1552-4469:139-40 (2012)

PMID: 22257852

A comprehensive comparison of transmembrane domains reveals organelle-specific properties.

Sharpe HJ, Stevens TJ, Munro S

142 1097-4172:158-69 (2010)

PMID: 20603021

Sequence-specific intramembrane proteolysis: identification of a recognition motif in rhomboid substrates.

Strisovsky K, Sharpe HJ, Freeman M

Molecular cell
36 1097-4164:1048-59 (2009)

PMID: 20064469